StockData
PepGen Inc. logo

PepGen Inc. (PEPG) stock

PEPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$4.36−0.68 (-13.49%)

Close on Nov 13, 2026Market cap $301.97MP/E –Yield –

Earnings

PepGen's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 3, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.28
-$0.52 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of PepGen's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 3, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open––-$0.28Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 12, 2026during market hours––-$0.26Release
Q4 FY2025ended Dec 31, 2025Mar 4, 2026during market hours––-$0.27Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open––-$0.52Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open––-$0.70Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open––-$0.92Release
Q4 FY2024ended Dec 31, 2024Feb 24, 2025before the open––-$0.68Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open––-$0.66Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open––-$0.87Release
Q1 FY2024ended Mar 31, 2024May 14, 2024during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

PepGen has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When PepGen puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases PepGen filed with the SEC as exhibits to Form 8-K or 6-K

  1. PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
    News
  2. PepGen Announces Pricing of $125 Million Public Offering
    News
  3. PepGen Reports Third Quarter 2026 Financial Results
    Results
  4. PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
    Results
  5. November 10, 2026 FREEDOM2-DM1 10 mg/kg MAD Cohort Data Update
    Results
  6. PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
    Results
  7. PGN-EDODM1 – Myotonic Dystrophy Type 1 (DM1)
    Results
  8. PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
    Results
  9. 8-K exhibit EX-99.1
    Update
  10. PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
    Results
  11. PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
    Update
  12. March 2026 FREEDOM2-DM1 5 mg/kg MAD Cohort Data Update
    Update
  13. PGN-EDODM1 – Myotonic Dystrophy Type 1 (DM1)
    Update
  14. PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
    Results
  15. PepGen Announces Regulatory Updates on FREEDOM2
    Results

See a number that looks wrong?